subcutaneous formulation
German Court Blocks Merck’s Subcutaneous Keytruda Over Patent Dispute with Halozyme
Merck; Keytruda SC; Halozyme; Germany; patent infringement; preliminary injunction; Munich Regional Court; subcutaneous formulation; cancer drug; MDASE patents
J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection
Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations